KRP-101

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H26FNO5
Molecular Weight	451.4867
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC[C@@H](CC1=CC(C(=O)NCC2=CC=C(OC3=CC=C(F)C=C3)C=C2)=C(OC)C=C1)C(O)=O

InChI

InChIKey=VRHOBXXCNBZJRX-IBGZPJMESA-N

InChI=1S/C26H26FNO5/c1-3-19(26(30)31)14-18-6-13-24(32-2)23(15-18)25(29)28-16-17-4-9-21(10-5-17)33-22-11-7-20(27)8-12-22/h4-13,15,19H,3,14,16H2,1-2H3,(H,28,29)(H,30,31)/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H26FNO5
Molecular Weight	451.4867
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Patents

Patents

Substance Class	Chemical
Record UNII	V123C0BB32
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

KRP-101

Common Name

English

KRP 101

Preferred Name

English

BENZENEPROPANOIC ACID, .ALPHA.-ETHYL-3-((((4-(4-FLUOROPHENOXY)PHENYL)METHYL)AMINO)CARBONYL)-4-METHOXY-, (.ALPHA.S)-

Systematic Name

English

(2S)-2-((3-((4-(4-FLUOROPHENOXY)PHENYL)METHYLCARBAMOYL)-4-METHOXY-PHENYL)METHYL)BUTANOIC ACID

Systematic Name

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

311770-26-0

PRIMARY

PUBCHEM

9825046

PRIMARY

FDA UNII

V123C0BB32

PRIMARY

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					V123C0BB32

KRP-101

ACTIVE MOIETY

Comments:

Kyorin Pharmaceutical Co. Ltd.'s PPAR.ALPHA. agonist, KRP-101, has completed Phase IIa testing to treat dyslipidemia.


					V123C0BB32

KRP-101

ACTIVE MOIETY

Comments:

The present study investigated the effects of a potent and subtype-selective PPARalpha agonist, KRP-101, in a nonrodent insulin-resistant animal model under pair-fed conditions. KRP-101 administration resulted in a significantly lower weight of overall visceral fat, which is associated with increased adiponectin and decreased leptin in serum. KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. Oral glucose tolerance test showed that KRP-101 administration improved glucose intolerance. The KRP-101 group showed a markedly lower hepatic triglyceride concentration.

Showing 1 to 2 of 2 entries

Previous1Next